281 related articles for article (PubMed ID: 37088914)
21. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
22. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
23. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
24. Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.
Henz K; Al-Zebeeby A; Basoglu M; Fulda S; Cohen GM; Varadarajan S; Vogler M
Biol Chem; 2019 Jan; 400(2):181-185. PubMed ID: 29924730
[TBL] [Abstract][Full Text] [Related]
25. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Lewis AC; Pope VS; Tea MN; Li M; Nwosu GO; Nguyen TM; Wallington-Beddoe CT; Moretti PAB; Anderson D; Creek DJ; Costabile M; Ali SR; Thompson-Peach CAL; Dredge BK; Bert AG; Goodall GJ; Ekert PG; Brown AL; D'Andrea R; Robinson N; Pitman MR; Thomas D; Ross DM; Gliddon BL; Powell JA; Pitson SM
Blood; 2022 Jun; 139(26):3737-3751. PubMed ID: 35443029
[TBL] [Abstract][Full Text] [Related]
26. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
27. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
28. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.
Skwarska A; Konopleva M
Cancer Res; 2023 Nov; 83(21):3501-3503. PubMed ID: 37824434
[TBL] [Abstract][Full Text] [Related]
29. The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics.
Smith KH; Budhraja A; Lynch J; Roberts K; Panetta JC; Connelly JP; Turnis ME; Pruett-Miller SM; Schuetz JD; Mullighan CG; Opferman JT
Mol Cancer Res; 2021 Apr; 19(4):636-650. PubMed ID: 33288732
[TBL] [Abstract][Full Text] [Related]
30. Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance.
Nakao F; Setoguchi K; Semba Y; Yamauchi T; Nogami J; Sasaki K; Imanaga H; Terasaki T; Miyazaki M; Hirabayashi S; Miyawaki K; Kikushige Y; Masuda T; Akashi K; Maeda T
Leukemia; 2023 May; 37(5):1028-1038. PubMed ID: 36973350
[TBL] [Abstract][Full Text] [Related]
31. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
[TBL] [Abstract][Full Text] [Related]
32. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
33. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.
Parry N; Busch C; Aßmann V; Cassels J; Hair A; Helgason GV; Wheadon H; Copland M
Cell Death Discov; 2022 Nov; 8(1):457. PubMed ID: 36379918
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract][Full Text] [Related]
36. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
37. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
[TBL] [Abstract][Full Text] [Related]
38. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
39. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
[TBL] [Abstract][Full Text] [Related]
40. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Moujalled DM; Brown FC; Chua CC; Dengler MA; Pomilio G; Anstee NS; Litalien V; Thompson E; Morley T; MacRaild S; Tiong IS; Morris R; Dun K; Zordan A; Shah J; Banquet S; Halilovic E; Morris E; Herold MJ; Lessene G; Adams JM; Huang DCS; Roberts AW; Blombery P; Wei AH
Blood; 2023 Feb; 141(6):634-644. PubMed ID: 36219880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
